A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Conditions:
🦠 Atopic Dermatitis 🦠 Alopecia Areata 🦠 Hidradenitis Suppurativa 🦠 Vitiligo 🦠 Psoriasis 🦠 Chronic Spontaneous Urticaria
πŸ—“οΈ Study Start (Actual) 21 December 2018
πŸ—“οΈ Primary Completion (Estimated) December 2050
βœ… Study Completion (Estimated) December 2050
πŸ‘₯ Enrollment (Estimated) 15000
πŸ”¬ Study Type OBSERVATIONAL
πŸ“Š Phase N/A
Locations:
πŸ“ Scottsdale, Arizona, United States
πŸ“ Fort Smith, Arkansas, United States
πŸ“ Little Rock, Arkansas, United States
πŸ“ Little Rock, Arkansas, United States
πŸ“ Fountain Valley, California, United States
πŸ“ Fremont, California, United States
πŸ“ Irvine, California, United States
πŸ“ San Diego, California, United States
πŸ“ Washington, District of Columbia, United States
πŸ“ Hollywood, Florida, United States
πŸ“ Tampa, Florida, United States
πŸ“ West Palm Beach, Florida, United States
πŸ“ Chicago, Illinois, United States
πŸ“ Indianapolis, Indiana, United States
πŸ“ Kansas City, Kansas, United States
πŸ“ Louisville, Kentucky, United States
πŸ“ Rockville, Maryland, United States
πŸ“ Quincy, Massachusetts, United States
πŸ“ Worcester, Massachusetts, United States
πŸ“ Minneapolis, Minnesota, United States
πŸ“ Rochester, Minnesota, United States
πŸ“ Missoula, Montana, United States
πŸ“ Lincoln, Nebraska, United States
πŸ“ Omaha, Nebraska, United States
πŸ“ Lebanon, New Hampshire, United States
πŸ“ East Windsor, New Jersey, United States
πŸ“ Wyckoff, New Jersey, United States
πŸ“ Bronx, New York, United States
πŸ“ Brooklyn, New York, United States
πŸ“ Buffalo, New York, United States
πŸ“ East Syracuse, New York, United States
πŸ“ Forest Hills, New York, United States
πŸ“ New York, New York, United States
πŸ“ New York, New York, United States
πŸ“ Rockville Centre, New York, United States
πŸ“ Asheville, North Carolina, United States
πŸ“ Chapel Hill, North Carolina, United States
πŸ“ Winston-Salem, North Carolina, United States
πŸ“ Columbus, Ohio, United States
πŸ“ Oklahoma City, Oklahoma, United States
πŸ“ Portland, Oregon, United States
πŸ“ Pittsburgh, Pennsylvania, United States
πŸ“ Charleston, South Carolina, United States
πŸ“ El Paso, Texas, United States
πŸ“ Frisco, Texas, United States
πŸ“ Lewisville, Texas, United States
πŸ“ Webster, Texas, United States
πŸ“ Murray, Utah, United States
πŸ“ Murray, Utah, United States
πŸ“ Richmond, Virginia, United States
πŸ“ Mill Creek, Washington, United States
πŸ“ Spokane, Washington, United States
πŸ“ Morgantown, West Virginia, United States
πŸ“ Milwaukee, Wisconsin, United States
πŸ“ Peterborough, Ontario, Canada
πŸ“ Richmond Hill, Ontario, Canada
πŸ“ MontrΓ©al, Quebec, Canada
πŸ“ Saskatoon, Saskatchewan, Canada
πŸ“ Mahlow, Bradenburg, Germany
πŸ“ DΓΌren, NRW, Germany
πŸ“ LΓΌbeck, Schleswig-Holstein, Germany
πŸ“ Barcelona, Spain
πŸ“ Madrid, Spain

πŸ“‹ Eligibility Criteria

Description

    Inclusion Criteria:

    • * 1. Adults and children (all ages) with Atopic Dermatitis or other Immune-mediated Inflammatory Skin Conditions been prescribed any dermatologic treatment.
    • * 2. Participant has plans for future visits at the site for continued management of IMISC.

    Exclusion Criteria:

    • * 1. Inability to provide written informed consent/assent.
    • * 2. Subjects participating in any interventional study or trial for IMISC treatment trial at the time of enrollment. Patients may be enrolled in TARGET-DERM once participation in the trial is complete. Note: Participants may be enrolled in other registries or studies where IMISC treatment outcomes are observed and/or reported (such as center-based registries).
Ages Eligible for Study: N/A to N/A (CHILD, ADULT, OLDER_ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No

πŸ—“οΈ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 4 September 2018
  • First Submitted that Met QC Criteria 4 September 2018
  • First Posted 7 September 2018

Study Record Updates

  • Last Update Submitted that Met QC Criteria 3 July 2024
  • Last Update Posted 5 July 2024
  • Last Verified March 2024